Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-dose HPV vaccine immunogenicity study in healthy girls aged 9-14 years
2011-002035-26Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in human papillomavirus infection, cervical intraepithelial neoplasia (CIN) and Cervical Cancer (CC) comparing Cervarix 2-dose schedule with Gardasil 2-dose schedule (2 arms). Primary endpoint: Immunogenicity at Month 7. Started Sep 2011; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenqHPV vaccine
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2011-002035-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002035-26.